Table 2
Molecular features of endometrial carcinoma, types I and II
| Type I/endometrioid carcinoma | Type II/non-endometrioid carcinoma | |
| Microsatellite instability | 20–40% | 0–5% |
| PTEN mutation | 35–50% | 10% |
| K-RAS mutation | 15–30% | 0–5% |
| PIK3CA mutation | 30% | 5% |
| β-Catenin/CTNNB1 mutation | 25–40% | 0–5% |
| p53 alteration | 10–20% | 90% |
| p16 inactivation | 10% | 40% |
| E-cadherin inactivation | 10–20% | 80–90% |
| c-erb B2 amplification | 2.5% | 26% |
| Cyclins D1 and E amplification | 2–5% | 26–42% |
